Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 643

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review

Ruopp, Nicole F., Cockrill, Barbara A.·2022·JAMA
DOI 10.1001/jama.2022.4402
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2022.4402

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 97

  1. Badesch, 2010, Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry., Chest, 137, 376, 10.1378/chest.09-1140 · DOI
  2. Frost, 2019, Diagnosis of pulmonary hypertension., Eur Respir J, 53, 10.1183/13993003.01904-2018 · DOI
  3. D’Alonzo, 1991, Survival in patients with primary pulmonary hypertension: results from a national prospective registry., Ann Intern Med, 115, 343, 10.7326/0003-4819-115-5-343 · DOI
  4. Galiè, 2019, Risk stratification and medical therapy of pulmonary arterial hypertension., Eur Respir J, 53, 10.1183/13993003.01889-2018 · DOI · Paper page
  5. Simonneau, 2019, Haemodynamic definitions and updated clinical classification of pulmonary hypertension., Eur Respir J, 53, 10.1183/13993003.01913-2018 · DOI · Paper page
  6. Maron, 2016, Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking program., Circulation, 133, 1240, 10.1161/CIRCULATIONAHA.115.020207 · DOI · Paper page
  7. Kim, 2019, Pulmonary hypertension., Med Clin North Am, 103, 413, 10.1016/j.mcna.2018.12.002 · DOI
  8. Stacher, 2012, Modern age pathology of pulmonary arterial hypertension., Am J Respir Crit Care Med, 186, 261, 10.1164/rccm.201201-0164OC · DOI · Paper page
  9. Tuder, 2017, Pulmonary vascular remodeling in pulmonary hypertension., Cell Tissue Res, 367, 643, 10.1007/s00441-016-2539-y · DOI
  10. Sun, 2003, Pulmonary function in primary pulmonary hypertension., J Am Coll Cardiol, 41, 1028, 10.1016/S0735-1097(02)02964-9 · DOI
  11. Vonk Noordegraaf, 2019, Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update., Eur Respir J, 53, 10.1183/13993003.01900-2018 · DOI
  12. Humbert, 2006, Pulmonary arterial hypertension in France: results from a national registry., Am J Respir Crit Care Med, 173, 1023, 10.1164/rccm.200510-1668OC · DOI
  13. Rich, 1987, Primary pulmonary hypertension: a national prospective study., Ann Intern Med, 107, 216, 10.7326/0003-4819-107-2-216 · DOI
  14. McGoon, 2013, Pulmonary arterial hypertension: epidemiology and registries., J Am Coll Cardiol, 62, D51, 10.1016/j.jacc.2013.10.023 · DOI
  15. Farber, 2015, Five-year outcomes of patients enrolled in the REVEAL registry., Chest, 148, 1043, 10.1378/chest.15-0300 · DOI
  16. Boucly, 2021, Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension., Am J Respir Crit Care Med, 204, 842, 10.1164/rccm.202009-3698OC · DOI
  17. Loyd, 1984, Familial primary pulmonary hypertension: clinical patterns., Am Rev Respir Dis, 129, 194
  18. Machado, 2009, Genetics and genomics of pulmonary arterial hypertension., J Am Coll Cardiol, 54, S32, 10.1016/j.jacc.2009.04.015 · DOI
  19. Morrell, 2019, Genetics and genomics of pulmonary arterial hypertension., Eur Respir J, 53, 10.1183/13993003.01899-2018 · DOI
  20. Harrison, 2003, Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia., J Med Genet, 40, 865, 10.1136/jmg.40.12.865 · DOI
  21. Sztrymf, 2008, Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation., Am J Respir Crit Care Med, 177, 1377, 10.1164/rccm.200712-1807OC · DOI · Paper page
  22. Girerd, 2010, Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation., Am J Respir Crit Care Med, 181, 851, 10.1164/rccm.200908-1284OC · DOI
  23. Zamanian, 2018, Features and outcomes of methamphetamine-associated pulmonary arterial hypertension., Am J Respir Crit Care Med, 197, 788, 10.1164/rccm.201705-0943OC · DOI
  24. Hachulla, 2005, Early detection of pulmonary arterial hypertension in systemic sclerosis., Arthritis Rheum, 52, 3792, 10.1002/(ISSN)1529-0131 · DOI
  25. Montani, 2012, Pulmonary arterial hypertension in patients treated by dasatinib., Circulation, 125, 2128, 10.1161/CIRCULATIONAHA.111.079921 · DOI
  26. Weatherald, 2017, Long-term outcomes of dasatinib-induced pulmonary arterial hypertension., Eur Respir J, 50, 10.1183/13993003.00217-2017 · DOI
  27. Shah, 2015, Clinical features of pulmonary arterial hypertension in patients receiving dasatinib., Am J Hematol, 90, 1060, 10.1002/ajh.24174 · DOI
  28. Mukerjee, 2003, Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach., Ann Rheum Dis, 62, 1088, 10.1136/ard.62.11.1088 · DOI
  29. Chung, 2010, Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype., Chest, 138, 1383, 10.1378/chest.10-0260 · DOI · Paper page
  30. Hachulla, 2009, Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study., Rheumatology (Oxford), 48, 304, 10.1093/rheumatology/ken488 · DOI
  31. Naranjo, 2021, Systemic sclerosis-associated pulmonary hypertension: spectrum and impact., Diagnostics (Basel), 11, 911, 10.3390/diagnostics11050911 · DOI
  32. Coghlan, 2014, Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study., Ann Rheum Dis, 73, 1340, 10.1136/annrheumdis-2013-203301 · DOI · Paper page
  33. Sitbon, 2008, Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era., Am J Respir Crit Care Med, 177, 108, 10.1164/rccm.200704-541OC · DOI
  34. Le Pavec, 2008, Portopulmonary hypertension: survival and prognostic factors., Am J Respir Crit Care Med, 178, 637, 10.1164/rccm.200804-613OC · DOI
  35. Krowka, 2006, Portopulmonary hypertension: results from a 10-year screening algorithm., Hepatology, 44, 1502, 10.1002/(ISSN)1527-3350 · DOI
  36. Krowka, 2012, Portopulmonary hypertension., Semin Respir Crit Care Med, 33, 17, 10.1055/s-0032-1301731 · DOI
  37. Al-Naamani, 2021, Estrogen signaling and portopulmonary hypertension: the Pulmonary Vascular Complications of Liver Disease Study (PVCLD2)., Hepatology, 73, 726, 10.1002/hep.v73.2 · DOI
  38. Martin, 2014, Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation., Hepatology, 59, 1144, 10.1002/hep.v59.3 · DOI
  39. Savale, 2017, Long-term outcome in liver transplantation candidates with portopulmonary hypertension., Hepatology, 65, 1683, 10.1002/hep.28990 · DOI
  40. Manes, 2014, Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease., Eur Heart J, 35, 716, 10.1093/eurheartj/eht072 · DOI · Paper page
  41. Hopkins, 2005, The remarkable right ventricle of patients with Eisenmenger syndrome., Coron Artery Dis, 16, 19, 10.1097/00019501-200502000-00004 · DOI
  42. Graham, 2010, Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective., Chest, 137, 20S, 10.1378/chest.10-0048 · DOI
  43. Sibomana, 2020, Schistosomiasis pulmonary arterial hypertension., Front Immunol, 11, 10.3389/fimmu.2020.608883 · DOI
  44. Mickael, 2019, The role of type 2 inflammation in Schistosoma-induced pulmonary hypertension., Front Immunol, 10, 27, 10.3389/fimmu.2019.00027 · DOI
  45. Masi, 2020, Clinical and preclinical imaging of hepatosplenic schistosomiasis., Trends Parasitol, 36, 206, 10.1016/j.pt.2019.11.007 · DOI
  46. Sitbon, 2005, Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension., Circulation, 111, 3105, 10.1161/CIRCULATIONAHA.104.488486 · DOI · Paper page
  47. Hemnes, 2016, Critical genomic networks and vasoreactive variants in idiopathic pulmonary arterial hypertension., Am J Respir Crit Care Med, 194, 464, 10.1164/rccm.201508-1678OC · DOI
  48. Rich, 1992, The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension., N Engl J Med, 327, 76, 10.1056/NEJM199207093270203 · DOI
  49. Lantuéjoul, 2006, Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis., Am J Surg Pathol, 30, 850, 10.1097/01.pas.0000209834.69972.e5 · DOI
  50. Montani, 2008, Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology., Medicine (Baltimore), 87, 220, 10.1097/MD.0b013e31818193bb · DOI
  51. Palmer, 1998, Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease., Chest, 113, 237, 10.1378/chest.113.1.237 · DOI
  52. Best, 2014, EIF2AK4 mutations in pulmonary capillary hemangiomatosis., Chest, 145, 231, 10.1378/chest.13-2366 · DOI
  53. Mandell, 2021, Persistent pulmonary hypertension of the newborn., Pediatr Pulmonol, 56, 661, 10.1002/ppul.v56.3 · DOI
  54. Steurer, 2017, Persistent pulmonary hypertension of the newborn in late preterm and term infants in California., Pediatrics, 139, 10.1542/peds.2016-1165 · DOI
  55. Brown, 2011, Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL registry., Chest, 140, 19, 10.1378/chest.10-1166 · DOI
  56. Ahearn, 2002, Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease., Chest, 122, 524, 10.1378/chest.122.2.524 · DOI
  57. Bonderman, 2011, A noninvasive algorithm to exclude pre-capillary pulmonary hypertension., Eur Respir J, 37, 1096, 10.1183/09031936.00089610 · DOI
  58. Simpson, 2020, Noninvasive prognostic biomarkers for left-sided heart failure as predictors of survival in pulmonary arterial hypertension., Chest, 157, 1606, 10.1016/j.chest.2019.12.037 · DOI
  59. Ullah, 2020, Comparative accuracy of non-invasive imaging versus right heart catheterization for the diagnosis of pulmonary hypertension., Int J Cardiol Heart Vasc, 29, 10.1016/j.ijcha.2020.100568 · DOI
  60. Ni, 2019, Diagnostic accuracy of transthoracic echocardiography for pulmonary hypertension., BMJ Open, 9, 10.1136/bmjopen-2019-033084 · DOI
  61. Amsallem, 2016, Addressing the controversy of estimating pulmonary arterial pressure by echocardiography., J Am Soc Echocardiogr, 29, 93, 10.1016/j.echo.2015.11.001 · DOI
  62. Farber, 2011, REVEAL registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension., Congest Heart Fail, 17, 56, 10.1111/j.1751-7133.2010.00202.x · DOI
  63. O’Leary, 2018, Lack of a tricuspid regurgitation Doppler signal and pulmonary hypertension by invasive measurement., J Am Heart Assoc, 7, 10.1161/JAHA.118.009362 · DOI
  64. Trip, 2013, Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension., Eur Respir J, 42, 1575, 10.1183/09031936.00184412 · DOI
  65. Pi, 2020, Outcomes of pulmonary arterial hypertension are improved in a specialty care center., Chest, 158, 330, 10.1016/j.chest.2020.01.046 · DOI
  66. Hoeper, 2006, Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers., J Am Coll Cardiol, 48, 2546, 10.1016/j.jacc.2006.07.061 · DOI
  67. Galiè, 2015, Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension., N Engl J Med, 373, 834, 10.1056/NEJMoa1413687 · DOI
  68. Sitbon, 2015, Selexipag for the treatment of pulmonary arterial hypertension., N Engl J Med, 373, 2522, 10.1056/NEJMoa1503184 · DOI
  69. Pulido, 2013, Macitentan and morbidity and mortality in pulmonary arterial hypertension., N Engl J Med, 369, 809, 10.1056/NEJMoa1213917 · DOI · Paper page
  70. Lajoie, 2016, Combination therapy versus monotherapy for pulmonary arterial hypertension., Lancet Respir Med, 4, 291, 10.1016/S2213-2600(16)00027-8 · DOI
  71. White, 2020, Combination therapy with oral treprostinil for pulmonary arterial hypertension., Am J Respir Crit Care Med, 201, 707, 10.1164/rccm.201908-1640OC · DOI
  72. Galiè, 2005, Sildenafil citrate therapy for pulmonary arterial hypertension., N Engl J Med, 353, 2148, 10.1056/NEJMoa050010 · DOI
  73. Galiè, 2009, Tadalafil therapy for pulmonary arterial hypertension., Circulation, 119, 2894, 10.1161/CIRCULATIONAHA.108.839274 · DOI
  74. Galiè, 2015, PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension., Eur Respir J, 45, 1314, 10.1183/09031936.00105914 · DOI
  75. Channick, 2001, Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension., Lancet, 358, 1119, 10.1016/S0140-6736(01)06250-X · DOI · Paper page
  76. Rubin, 2002, Bosentan therapy for pulmonary arterial hypertension., N Engl J Med, 346, 896, 10.1056/NEJMoa012212 · DOI · Paper page
  77. Barst, 1996, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension., N Engl J Med, 334, 296, 10.1056/NEJM199602013340504 · DOI · Paper page
  78. Simonneau, 2002, Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension., Am J Respir Crit Care Med, 165, 800, 10.1164/ajrccm.165.6.2106079 · DOI · Paper page
  79. Humbert, 2004, Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2., Eur Respir J, 24, 353, 10.1183/09031936.04.00028404 · DOI · Paper page
  80. Hoeper, 2006, Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension., Eur Respir J, 28, 691, 10.1183/09031936.06.00057906 · DOI · Paper page
  81. McLaughlin, 2015, Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension., Eur Respir J, 46, 405, 10.1183/13993003.02044-2014 · DOI
  82. Galiè, 2008, Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study)., Lancet, 371, 2093, 10.1016/S0140-6736(08)60919-8 · DOI
  83. Tapson, 2012, Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study)., Chest, 142, 1383, 10.1378/chest.11-2212 · DOI
  84. Tapson, 2013, Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study)., Chest, 144, 952, 10.1378/chest.12-2875 · DOI
  85. Simonneau, 2008, Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension., Ann Intern Med, 149, 521, 10.7326/0003-4819-149-8-200810210-00004 · DOI · Paper page
  86. McLaughlin, 2006, Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension., Am J Respir Crit Care Med, 174, 1257, 10.1164/rccm.200603-358OC · DOI
  87. Chin, 2021, Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension., J Am Coll Cardiol, 78, 1393, 10.1016/j.jacc.2021.07.057 · DOI
  88. McLaughlin, 2010, Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension., J Am Coll Cardiol, 55, 1915, 10.1016/j.jacc.2010.01.027 · DOI · Paper page
  89. Zhuang, 2014, Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension., Hypertens Res, 37, 507, 10.1038/hr.2014.28 · DOI
  90. Sitbon, 2016, Beyond a single pathway: combination therapy in pulmonary arterial hypertension., Eur Respir Rev, 25, 408, 10.1183/16000617.0085-2016 · DOI
  91. Klinger, 2019, Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report., Chest, 155, 565, 10.1016/j.chest.2018.11.030 · DOI · Paper page
  92. Maron, 2020, Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension., Br J Pharmacol, 177, 1457, 10.1111/bph.v177.7 · DOI
  93. Weitzenblum, 1985, Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease., Am Rev Respir Dis, 131, 493, 10.1164/arrd.1985.131.4.493 · DOI · Paper page
  94. Hemnes, 2015, Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute., Pulm Circ, 5, 435, 10.1086/682230 · DOI · Paper page
  95. Jaïs, 2012, Pregnancy outcomes in pulmonary arterial hypertension in the modern management era., Eur Respir J, 40, 881, 10.1183/09031936.00141211 · DOI
  96. Fessel, 2013, Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension., Pulm Circ, 3, 564, 10.1086/674312 · DOI
  97. Wertheim, 2017, Brigham Intensive Review of Internal Medicine, 339

Cited by

See all 643

Metadata

Authors
Ruopp, N. F., & Cockrill, B. A.
Affiliations
  • Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, Boston, Massachusetts
  • Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2022-04-12
Volume
327
Issue
14
Pages
1379
ISSN
0098-7484
DOI
10.1001/jama.2022.4402
Cited by
643
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. https://app.cochat.ai/papers/10.1001/jama.2022.4402
The paper
Ruopp, N. F., & Cockrill, B. A. (2022). Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. https://doi.org/10.1001/jama.2022.4402

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.